Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Zhan Yao, Rona Yaeger, Vanessa S. Rodrik-Outmezguine, Anthony Tao, Neilawattie M. Torres, Matthew T. Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough, Judith Michels, Hervé Baumert, Linde Miles, Naomi M. Campbell, Elisa de Stanchina, David B. Solit, Mariano Barbacid, Barry S. Taylor and Neal Rosen ()
Additional contact information
Zhan Yao: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Rona Yaeger: Memorial Sloan Kettering Cancer Center
Vanessa S. Rodrik-Outmezguine: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Anthony Tao: Center for Neural Science, College of Arts and Sciences, New York University
Neilawattie M. Torres: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Matthew T. Chang: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Matthias Drosten: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO)
Huiyong Zhao: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Fabiola Cecchi: Molecular Oncology Group, NantOmics, LLC, 9600 Medical Center Drive
Todd Hembrough: Molecular Oncology Group, NantOmics, LLC, 9600 Medical Center Drive
Judith Michels: Gustave Roussy Cancer Campus
Hervé Baumert: Saint Joseph Hospital
Linde Miles: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
Naomi M. Campbell: Memorial Sloan Kettering Cancer Center
Elisa de Stanchina: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
David B. Solit: Memorial Sloan Kettering Cancer Center
Mariano Barbacid: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO)
Barry S. Taylor: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Neal Rosen: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center

Nature, 2017, vol. 548, issue 7666, 234-238

Abstract: Hypoactive BRAF mutants bind more tightly than wild type to the upstream regulator RAS, thus amplifying to amplify ERK signalling; tumours expressing these mutants require coexistent mechanisms for RAS activation to grow and are sensitive to their inhibition.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature23291 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:548:y:2017:i:7666:d:10.1038_nature23291

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature23291

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().